Arrowhead Pharmaceuticals Inc (ARWR) Short Interest Update

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) was the target of a large growth in short interest during the month of January. As of January 12th, there was short interest totalling 4,478,905 shares, a growth of 51.3% from the December 29th total of 2,959,910 shares. Based on an average trading volume of 3,400,352 shares, the short-interest ratio is presently 1.3 days. Approximately 7.0% of the shares of the stock are sold short.

A number of brokerages recently weighed in on ARWR. ValuEngine upgraded Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd. Piper Jaffray Companies upgraded Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price objective on the stock in a research report on Monday, November 27th. BidaskClub lowered Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Chardan Capital restated a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 16th. Finally, B. Riley began coverage on Arrowhead Pharmaceuticals in a research report on Friday, January 5th. They set a “neutral” rating and a $3.00 price objective on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Arrowhead Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $3.13.

In related news, COO Bruce D. Given sold 20,000 shares of the business’s stock in a transaction on Monday, January 1st. The stock was sold at an average price of $3.69, for a total transaction of $73,800.00. Following the sale, the chief operating officer now owns 948,356 shares in the company, valued at approximately $3,499,433.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.57% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. grew its position in shares of Arrowhead Pharmaceuticals by 8.8% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 186,381 shares of the biotechnology company’s stock valued at $686,000 after buying an additional 15,132 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Arrowhead Pharmaceuticals by 252.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 31,765 shares during the last quarter. Virtu KCG Holdings LLC grew its position in shares of Arrowhead Pharmaceuticals by 115.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 53,215 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Arrowhead Pharmaceuticals by 1,177.7% in the 4th quarter. Acadian Asset Management LLC now owns 71,664 shares of the biotechnology company’s stock valued at $264,000 after buying an additional 66,055 shares during the last quarter. Finally, Allianz Asset Management GmbH bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $1,958,000. Hedge funds and other institutional investors own 20.05% of the company’s stock.

Shares of Arrowhead Pharmaceuticals (NASDAQ ARWR) opened at $6.12 on Friday. The firm has a market capitalization of $542.73, a price-to-earnings ratio of -13.30 and a beta of 1.79. Arrowhead Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $6.75. The company has a current ratio of 3.63, a quick ratio of 3.63 and a debt-to-equity ratio of 0.03.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Tuesday, December 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Arrowhead Pharmaceuticals had a negative net margin of 109.46% and a negative return on equity of 38.10%. analysts forecast that Arrowhead Pharmaceuticals will post -0.74 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Arrowhead Pharmaceuticals Inc (ARWR) Short Interest Update” was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/01/28/arrowhead-pharmaceuticals-inc-arwr-short-interest-update.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply